Browse All

Current Filters

CLEAR FILTER x

TITLE

Efficacy and Safety of Rimegepant for the Acute Treatment of Migraine in Japan

Author:Matsumori, Yasuhiko   Ikeda, Koichi   Kudo, Masako   Ishikawa, Tomofumi   Hoshino, Yuko   Yoshimatsu, Hiroki   Thiry, Alexandra   Arakawa, Akio   Croop, Robert   Fullerton, Terence   Sakai, Fumihiko   Takeshima, Takao   

Session Name:P8: Headache: Health Equity, Disparities, and Global Research 2  

Topic:Headache  

Program Number:P8.006  

Author Institution:

Efficacy and Safety of Rimegepant for the Prevention of Migraine in Japan

Author:Matsumori, Yasuhiko   Kitamura, Shigekazu   Yamamoto, Toshimasa   Ishikawa, Tomofumi   Hoshino, Yuko   Yoshimatsu, Hiroki   Thiry, Alexandra   Arakawa, Akio   Croop, Robert   Fullerton, Terence   Sakai, Fumihiko   Takeshima, Takao   

Session Name:P8: Headache: Health Equity, Disparities, and Global Research 2  

Topic:Headache  

Program Number:P8.007  

Author Institution:

Time to First and Sustained Improvement in Weekly Migraine Days Among Patients Receiving Preventive Treatment With Rimegepant 75 mg

Author:Tepper, Stewart   Abraham, Lucy   Bushmakin, Andrew   Cappelleri, Joseph   Fullerton, Terence   Yang, Jiyue   Lipton, Richard   

Session Name:P9: Headache: Advances in CGRP Inhibitors and Migraine 2  

Topic:Headache  

Program Number:P9.005  

Author Institution:New England Institute for Neurology and Headache, Stamford, CT  Pfizer R&D UK Ltd, Tadworth, United Kingdom  Pfizer Inc, Groton, CT  Pfizer Inc, New York, NY  Montefiore Headache Center and the Albert Einstein College of Medicine, New York, NY  

Efficacy and Safety of Once-daily Rimegepant 75 mg Orally Disintegrating Tablet for the Short-term Preventive Treatment of Fasting-related Headache

Author:Alsaadi, Taoufik   Suliman, Reem   Yang, Jiyue   Agarwal, Ekta   Fullerton, Terence   Chou, Denise E.   Whalen, Ed   El Jadam, Caline   Al Qaisi, Ibrahim   Amin, Youssef   Alkhateri, Athra   Alsaffarini, Kareem   Abraham, Lucy   Zunaed, Zahra   Ahmed, Haytham M.   Fathy, Mohamed   Hegab,   

Session Name:P10: Headache: Advances in CGRP Inhibitors and Migraine 3  

Topic:Headache  

Program Number:P10.010  

Author Institution:American Center for Psychiatry and Neurology, Abu Dhabi, UAE, Abu Dhabi, United Arab Emirates  Pfizer Inc, New York, NY, USA, New York, NY  Pfizer Inc, Groton, CT, USA, Groton, CT  Pfizer Inc, Cambridge, MA, USA, Cambridge, MA  Pfizer Ltd, Tadworth, UK, Tadworth, United Kingdom  Pfizer Gulf FZ LLC, Dubai Media City, Dubai, UAE, Dubai Media City, Dubai, United Arab Emirates  Pfizer, Buenos Aires, Argentina, Buenos Aires, Argentina  

A Phase 4, Open-label Study Evaluating the Safety and Tolerability of Once Daily Rimegepant for Episodic Migraine Prevention

Author:Antinew, Jeremias   Fountaine, Robert   Loprinzo, Vittorio   Straghan, Esther   Fullerton, Terence   

Session Name:P11: Emerging Science  

Topic:Headache  

Program Number:P11.008  

Author Institution:Pfizer Inc, Groton, CT  Pfizer Inc, New York, NY  Pfizer Ltd., Surrey, United Kingdom